LIBRETTO-431 East Asia Subgroup Results of First-line Selpercatinib vs Chemotherapy + Pembrolizumab in RET Fusion–Positive NSCLC
oncodaily.com/oncolibrary/...
#OncoDaily #Oncology #Cancer #Health #Medicine #MedEd #MedOnc #MedNews #LIBRETTO431 #Selpercatinib #Pembrolizumab #NSCLC #LungCancer #IO
4
1
0
0